Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder

First Posted Date
2009-12-18
Last Posted Date
2011-04-14
Lead Sponsor
Sanofi
Target Recruit Count
580
Registration Number
NCT01034995
Locations
🇪🇪

Sanofi-Aventis Investigational Site Number 233003, Tartu, Estonia

🇨🇱

Sanofi-Aventis Investigational Site Number 152007, Valparaiso, Chile

🇫🇮

Sanofi-Aventis Investigational Site Number 246005, Järvenpää, Finland

and more 70 locations

Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-12-02
Last Posted Date
2009-12-02
Lead Sponsor
Northern California Institute of Research and Education
Target Recruit Count
16
Registration Number
NCT01024140

AZD7268 Safety and Tolerability Study

First Posted Date
2009-11-26
Last Posted Date
2012-04-17
Lead Sponsor
AstraZeneca
Target Recruit Count
247
Registration Number
NCT01020799
Locations
🇺🇸

Research Site, Seattle, Washington, United States

The Effect of Selective Serotonin Reuptake Inhibitor (SSRI) Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing in Vitro Fertilization (IVF)

First Posted Date
2009-10-02
Last Posted Date
2009-10-02
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
120
Registration Number
NCT00989053
Locations
🇮🇱

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

A Study of Patients With Major Depressive Disorder and Residual Apathy

First Posted Date
2009-09-28
Last Posted Date
2011-12-13
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
483
Registration Number
NCT00985504
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight

First Posted Date
2009-09-04
Last Posted Date
2017-06-05
Lead Sponsor
University of Aarhus
Target Recruit Count
60
Registration Number
NCT00971815
Locations
🇩🇰

Medical Dep M, Diabetes and Endocrinology Aarhus University Hospital, Aarhus Sygehus, Aarhus, Denmark

Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients

First Posted Date
2009-08-27
Last Posted Date
2009-08-27
Lead Sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita
Target Recruit Count
200
Registration Number
NCT00967408
Locations
🇮🇹

Physical medicine & rehabilitation Dept AOU Maggiore della Carità, Novara, Italy

Escitalopram (Lexapro) for Depression MS or ALS

First Posted Date
2009-08-25
Last Posted Date
2019-05-01
Lead Sponsor
University of South Carolina
Target Recruit Count
13
Registration Number
NCT00965497
Locations
🇺🇸

University of South Carolina School of Medicine, Columbia, South Carolina, United States

Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-08-13
Last Posted Date
2023-06-05
Lead Sponsor
University of British Columbia
Target Recruit Count
178
Registration Number
NCT00958633
Locations
🇨🇦

University of British Columbia, Vancouver, British Columbia, Canada

© Copyright 2024. All Rights Reserved by MedPath